Stock VENUSREM VENUS REMEDIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Venus Remedies Limited NSE India S.E.

Equities

VENUSREM

INE411B01019

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 08:53:37 14/05/2024 BST 		5-day change 1st Jan Change
303.4 INR +2.95% Intraday chart for Venus Remedies Limited -2.27% -25.32%
03-19 Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs MT
03-08 Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products MT

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 810.3 409.1 277.7 3,389 3,594 2,165
Enterprise Value (EV) 1 3,841 3,369 2,463 3,614 3,590 1,874
P/E ratio -2.64 x -1.43 x -2.78 x 5.49 x 8.71 x 8.15 x
Yield - - - - - -
Capitalization / Revenue 0.22 x 0.13 x 0.08 x 0.6 x 0.6 x 0.39 x
EV / Revenue 1.03 x 1.05 x 0.72 x 0.64 x 0.6 x 0.34 x
EV / EBITDA 10.4 x 11.9 x 6.42 x 5.65 x 6.02 x 3.24 x
EV / FCF 28.9 x 13.5 x -22.3 x 2.31 x 95.1 x 12 x
FCF Yield 3.46% 7.4% -4.48% 43.4% 1.05% 8.37%
Price to Book 0.22 x 0.12 x 0.09 x 0.85 x 0.82 x 0.47 x
Nbr of stocks (in thousands) 12,342 12,342 12,342 12,342 13,367 13,367
Reference price 2 65.65 33.15 22.50 274.6 268.8 162.0
Announcement Date 28/08/18 04/09/19 09/11/20 17/08/21 29/07/22 22/07/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,724 3,219 3,415 5,604 5,986 5,555
EBITDA 1 369.9 283.4 383.8 639.2 596.7 577.8
EBIT 1 76.42 -11.54 98.56 315.1 290.4 283.9
Operating Margin 2.05% -0.36% 2.89% 5.62% 4.85% 5.11%
Earnings before Tax (EBT) 1 -275.3 -297.2 -80.35 485.5 364.1 379.3
Net income 1 -306.9 -285.7 -99.99 617.7 407.2 265.7
Net margin -8.24% -8.88% -2.93% 11.02% 6.8% 4.78%
EPS 2 -24.87 -23.16 -8.103 50.04 30.86 19.87
Free Cash Flow 1 132.8 249.3 -110.3 1,567 37.73 156.8
FCF margin 3.57% 7.75% -3.23% 27.97% 0.63% 2.82%
FCF Conversion (EBITDA) 35.9% 87.98% - 245.16% 6.32% 27.15%
FCF Conversion (Net income) - - - 253.72% 9.26% 59.04%
Dividend per Share - - - - - -
Announcement Date 28/08/18 04/09/19 09/11/20 17/08/21 29/07/22 22/07/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 3,031 2,960 2,185 224 - -
Net Cash position 1 - - - - 4.11 291
Leverage (Debt/EBITDA) 8.193 x 10.44 x 5.694 x 0.351 x - -
Free Cash Flow 1 133 249 -110 1,567 37.7 157
ROE (net income / shareholders' equity) -8.18% -8.23% -3.05% 17.1% 9.69% 5.9%
ROA (Net income/ Total Assets) 0.63% -0.1% 0.9% 3.28% 3.2% 3.01%
Assets 1 -48,702 293,978 -11,124 18,810 12,740 8,841
Book Value Per Share 2 293.0 269.0 262.0 324.0 330.0 344.0
Cash Flow per Share 2 3.230 1.650 1.570 23.40 32.40 15.90
Capex 1 141 99.2 77.8 - 137 78.2
Capex / Sales 3.79% 3.08% 2.28% - 2.29% 1.41%
Announcement Date 28/08/18 04/09/19 09/11/20 17/08/21 29/07/22 22/07/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.89% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.42% 240B
NOVARTIS AG Stock Novartis AG
+9.37% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-9.24% 203B
AMGEN INC. Stock Amgen Inc.
+7.09% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VENUSREM Stock
  4. VENUSREM Stock
  5. Financials Venus Remedies Limited